Hydroxychloroquine may reduce risk of Pneumocystis pneumonia in lupus patients: a Nationwide, population-based case-control study

Hydroxychloroquine may reduce risk of Pneumocystis pneumonia in lupus patients: a Nationwide, population-based case-control study

Abstract Background Pneumocystis pneumonia (PCP) is increasingly being diagnosed in patients with systemic lupus erythematosus (SLE), and hydroxychloroquine (HCQ) has been found to possess antifungal activities. We hence aimed to investigate the association between HCQ and PCP risk among patients wi...

Full description

Bibliographic Details
Main Authors: Kai-Jieh Yeo, Hsin-Hua Chen, Yi-Ming Chen, Ching-Heng Lin, Der-Yuan Chen, Chih-Ming Lai, Wen-Cheng Chao
Format: Article
Language:English
Published: BMC 2020-02-01
Series:BMC Infectious Diseases
Subjects:
Lupus
Pneumocystis pneumonia
Hydroxychloroquine
Glucocorticoid
Mycophenolate mofetil
Online Access:https://doi.org/10.1186/s12879-020-4826-1

Similar Items

Similar Items